Pertussis: acellular, whole-cell, new vaccines, what to choose?

Locht, Camille

doi:10.1586/14760584.2016.1161511

Cited by 14 publications

(10 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whooping cough is a highly contagious disease caused by Bordetella pertussis. Since the introduction of the vaccine against its agent in the mid-20 th century infection rates dropped dramatically for the US reaching as low as <1 per 100'000 in the 70s (41). For decades inactivated B. pertussis was supplemented by diphtheria and tetanus toxoids to formulate DTwP vaccine.…”

Section: Discussionmentioning

confidence: 99%

A system-view ofB. pertussisbooster vaccine responses in adults primed with whole-cell vs. acellular vaccine in infancy

Antunes

Pomaznoy

Soldevila

et al. 2020

Preprint

View full text Add to dashboard Cite

Whole-cell inactivated vaccine against Bordetella pertussis (wP) was substituted in many countries by an acellular subunit vaccine (aP) to reduce side effects. Recent epidemiological studies have shown that aP vaccination in infancy induces less durable immunity than wP vaccination. To determine immunological differences associated with aP vs. wP priming, we performed system-level profiling of the immune response in adults primed with aP vs. wP vaccine in infancy following the Tdap booster vaccination as a surrogate to antigen encounter in vivo.Shared immune responses across cohorts were identified, including an increase of the blood monocyte frequency on day 1, and strong antigen-specific IgG response seven days after boost.Comparing aP and wP primed individuals, we found a subset of aP-primed individuals with higher levels of expression for several genes including CCL3 on day 3 and NFKBIA and ICAM1 on day 7 post immunization. These observations were supported by increased CCL3 concentrations in plasma of aP primed individuals. Contrary to the wP individuals, the CCL3-high aP subset presented boosted PT-specific IgE responses. Furthermore, higher antigen specific IgG4 and IgG3

show abstract

Section: Discussionmentioning

confidence: 99%

A system-view ofB. pertussisbooster vaccine responses in adults primed with whole-cell vs. acellular vaccine in infancy

Antunes

Pomaznoy

Soldevila

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, immunization at birth with pertussis vaccines resulted in a reduced response to pertussis boosters at up to 5 months of age, which was independent of maternal Abs [80]. Conversely, if immunization was delayed until 3 weeks of age the serological response to pertussis was significantly improved [81,82]. A study of rotavirus vaccine similarly found the response was less robust, the earlier in life the vaccine was given [83].…”

Section: Lessons From Successful Neonatal Vaccinesmentioning

confidence: 99%

Neonatal vaccine effectiveness and the role of adjuvants

Sakala

Eichinger

Petrovsky

2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Neonates are less responsive to vaccines than adults, making it harder to protect newborns against infection. Neonatal differences in antigen-presenting cell, B and T cell function, all likely contribute.A key question is whether novel adjuvants might be able to make neonatal vaccines more effective. Areas covered: This review addresses the issues of how to improve neonatal vaccines, which we have defined as vaccines given in the first 4 weeks of life in a human infant or the first week of life in a mouse. A search was performed using keywords including 'neonatal immunity', 'neonatal immunisation', 'vaccine' and 'adjuvant' of PubMed articles published between 1960 and 2018. Expert opinion: Sugar-like structures have recently been shown to prime the infant adaptive immune system to respond to vaccines, being potentially more effective than traditional adjuvants. Sugar-based compounds with beneficial adjuvant effects in neonatal vaccine models include delta inulin (Advax), curdlan, and trehalose 6,6ʹ-dibehenate. Such compounds make interesting neonatal adjuvant candidates, either used alone or in combination with traditional innate immune adjuvants. ARTICLE HISTORY

show abstract

“…Since current aPVs mainly elicit a Th2 response, several solutions have been proposed to improve the Th1/Th17 responses. One possibility is to combine these vaccines with Th1driving adjuvants, at least for the priming doses [46,51]. The development of such a candidate vaccine based on a single-immunization platform consisting of three immune stimulators is in progress [47], namely, (i) host defense peptides, (ii) polyphosphazenes (a family of inorganic molecular hybrid polymers based on a phosphorus-nitrogen backbone substituted with organic side groups with very diverse properties), and (iii) the synthetic oligonucleotides containing CpG-ODN (oligodeoxynucleotides) combined with poly(I:C), (polyinosinic-polycytidylic acid) an agonists of Toll-like receptor 9 (TLR9).…”

Section: Resurgence Vaccine Design and New Targetsmentioning

confidence: 99%

Preventive and Protective Properties of Pertussis Vaccines: Current Situation and Future Challenges

Sg¹,

Dw²,

F³

2018

Pertussis - Disease, Control and Challenges

View full text Add to dashboard Cite

Pertussis, more commonly known as whooping cough, is a potentially fatal respiratory disease caused by Bordetella pertussis. Two different types of vaccines provide effective protection: killed whole-cell vaccines (wPV) and more recently available acellular vaccines (aPVs) formulated with specific components. Disturbingly, while the vaccines are widely used, the incidence of disease is increasing in several developed countries that have switched from wPV to an aPV. It is suggested that the single most important underlying cause suggested for the resurgence is transmission through asymptomatic infections. While both vaccines protect against disease, a newly developed baboon model has shown that they do not prevent infection. Importantly, wPV-vaccinated animals appeared to clear an infection more rapidly than those vaccinated with aPV, which can relate to the period of possible disease transmission. To ultimately control whooping cough, it is clear that a more effective vaccine is needed that can prevent both disease and transmission. Modifications underway include the elimination of LPS from wPVs to improve their safety profiles and augmentation of aPVs with other bacterium proteins to increase immunogenicity and the longevity of protection. In the interim, vaccinations with aPV during pregnancy appear to protect newborns, the most susceptible to deadly pertussis.

show abstract

Pertussis: acellular, whole-cell, new vaccines, what to choose?

Cited by 14 publications

References 16 publications

A system-view ofB. pertussisbooster vaccine responses in adults primed with whole-cell vs. acellular vaccine in infancy

A system-view ofB. pertussisbooster vaccine responses in adults primed with whole-cell vs. acellular vaccine in infancy

Neonatal vaccine effectiveness and the role of adjuvants

Preventive and Protective Properties of Pertussis Vaccines: Current Situation and Future Challenges

Contact Info

Product

Resources

About